SPRY3, an antagonist of the fibroblast growth factor (FGF) pathway [120], was identified as a therapeutic modulator in a genome-wide CRISPR library screen (64,751 sgRNAs targeting 18,080 genes) performed in an FLT3-mutant AML cell line (MV4-11) treated with a second-generation FLT-3 inhibitor AC220 [32]. This evidence concerns the gene FLT3 and acute myeloid leukemia.